端粒酶
端粒
癌症研究
癌症
端粒酶逆转录酶
医学
生物
癌细胞
遗传学
DNA
基因
出处
期刊:Nature Reviews Cancer
[Springer Nature]
日期:2008-03-01
卷期号:8 (3): 167-179
被引量:621
摘要
Telomerase is an attractive cancer target as it appears to be required in essentially all tumours for immortalization of a subset of cells, including cancer stem cells. Moreover, differences in telomerase expression, telomere length and cell kinetics between normal and tumour tissues suggest that targeting telomerase would be relatively safe. Clinical trials are ongoing with a potent and specific telomerase inhibitor, GRN163L, and with several versions of telomerase therapeutic vaccines. The prospect of adding telomerase-based therapies to the growing list of new anticancer products is promising, but what are the advantages and limitations of different approaches, and which patients are the most likely to respond?
科研通智能强力驱动
Strongly Powered by AbleSci AI